Back to Selection     Print       Date : 30 Jun 2025
Fund Summary
Canara Robeco Focused Fund Reg (G)
[Equity: Focused]  
 
Fund Details
Fund Type Growth Launch Date 17-May-2021
Corpus(Cr.) 2743.0 Latest NAV 19.98 As on 30-07-2025
Equity(%) 94.79 52 Week High 20.51
Debt(%) 5.21 52 Week Low 17.03
Others(%) 0.0 Exit Load -
Minimum Investment - Availability
Entry Load Nil Expense Ratio(%) 1.93
Scheme Benchmark BSE 500 TRI Broader Benchmark NSE - Nifty 50 TRI
Fund Manager Amit Kadam
 
Riskometer
Investors understand that their principal will be at Very High risk
 
Scheme Objective
The scheme seeks to generate long term capital appreciation/income by investing in equity and equity related instruments across market capitalization of up to 30 companies.

Portfolio Classification
 
Asset Mix
 
Concentration Analysis
Top 5 Holdings 30.62%
Top 10 Holdings 50.39%
Top 25 Holdings 91.18%
 
Sector Analysis
Sector/Ratings Net Asset(%)
Banking & Financial 20.76
Retail 10.24
Automobile 8.8
Construction 6.59
Software & Services 6.54
Healthcare 5.97
Pharma & Biotech 5.88
Cash 5.21
Telecom 4.32
Petroleum Products 4.25
Finance & Investments 3.84
Miscellaneous 3.54
Electricals 3.41
Aerospace & Defence 2.67
Paper 2.12
Food Beverage & Tobacco 2.11
SERVICES 1.91
Transportation 1.84
 
 
 
 
 
Portfolio Metrics
PB Ratio 5.62
PE Ratio 35.66
 
Top 25 Holdings
Holdings Net Asset(%)
ICICI Bank Limited 8.56
HDFC Bank Limited 8.08
TREPS 5.31
Infosys Limited 4.35
Bharti Airtel Limited 4.32
Reliance Industries Limited 4.25
DIVI LABORATORIES LTD. 3.91
Larsen & Toubro Limited 3.90
Eternal Limited 3.86
Trent Limited 3.85
Max Healthcare Institute Limited 3.84
Bajaj Finance Limited 3.84
TVS Motor Co Ltd 3.81
GE T&D INDIA LIMITED 3.41
Minda Industries Ltd 2.96
UltraTech Cement Limited 2.69
Bharat Electronics Limited 2.67
Avenue Supermarts Limited 2.53
Axis Bank Limited 2.49
Tata Consultancy Services Limited 2.19
Dr Agarwals Health Care Limited 2.13
Aditya Birla Real Estate Limited 2.12
Varun Beverages Limited 2.11
Maruti Suzuki India Limited 2.03
Mankind Pharma Limited 1.97

Performance Analysis
 
Short Terms Returns
1 Month 3 Month 6 Month 1 Year
-1.38% 7.07% 10.14% 6.73%
 
Broader Market Benchmark [NSE - Nifty 50 TRI]
-2.43% 2.80% 7.76% 1.27%
 
Scheme Benchmark [NSE - Nifty 500 TRI]
-2.33% 5.05% 8.82% -0.75%
 
Long term Returns
2 Year 3 Year 5 Year 10 Year
20.10% 18.72% 0.00% 0.00%
 
 
13.82% 14.44% 18.90% 12.79%
 
 
17.65% 17.31% 21.83% 13.86%
 
Cumulative Performance of Last 5 Years
 
Calendar Year Returns

Risk Analysis
 
Absolute Metrics (Single Computation - last 3 years)
Scheme Name Standard Deviation Sharpe Ratio Downside Deviation Downside Probability Sortino Ratio
 
Benchmark Relative Metrics (Single Computation - last 3 years)
Scheme Name Alpha Beta Treynor Ratio Tracking Error Information Ratio
 
Back to Selection